Compare AstraZeneca plc (AZN) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Oklo Inc — how do they compare? AstraZeneca plc trades at $158.6 (market cap $248.14B), while Oklo Inc trades at $45.5 (market cap $8.74B). The key difference: AstraZeneca plc is far larger — about 28.4× Oklo Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Oklo Inc pays none. Which is the better fit depends on your goals.
| AZN | OKLO | |
|---|---|---|
Market Cap | $248.14B | $8.74B |
Sector | Health | Technology |
52-Week High | $209.48 | $174.14 |
52-Week Low | $147.06 | $36.84 |
Enterprise Value | $275.41B | $6.28B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
OKLO trades at $45.71, up 2.74% with a bullish technical outlook despite recent volatility. The company reported its first revenue of $1.2 million in Q2 2026 but continues to post significant losses (-$105.66M net income in 2025) with negative margins. Analyst consensus remains strongly bullish with a $77.07 price target, though CEO share sales and high cash burn present near-term concerns.
While OKLO shows promising nuclear technology development with recent milestones, investors face substantial execution risks amid widening losses and negative cash flow. The stock offers high growth potential in the emerging nuclear energy sector but requires careful risk management given the pre-profitability stage and volatile price action.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
